Downregulation of miR‑146a inhibits osteoporosis in the jaws of ovariectomized rats by regulating the Wnt/β‑catenin signaling pathway

Liu,Hua; Yue,Xianhu; Zhang,Gang

doi:10.3892/ijmm.2020.4839

Downregulation of miR‑146a inhibits osteoporosis in the jaws of ovariectomized rats by regulating the Wnt/β‑catenin signaling pathway

Authors:
- Hua Liu
- Xianhu Yue
- Gang Zhang
View Affiliations

Affiliations: Department of Orthopedics, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, Shandong 250031, P.R. China
Published online on: December 30, 2020 https://doi.org/10.3892/ijmm.2020.4839
Article Number: 6
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs or miRs) play important roles in osteoporosis and exhibit high potential in the therapeutic treatment of this condition. The present study aimed to explore the effects of miR‑146a on bone loss noted in the jawbones of ovariectomized (OVX) rats and the interaction of miR‑146a with the Wnt/β‑catenin signaling pathway. OVX Sprague‑Dawley female rats were used to establish the animal model of osteoporosis (OP). Bone mineral density (BMD) was measured via dual‑energy X‑ray and the miR‑146a levels were detected by reverse transcription‑quantitative PCR. miR‑146a antagonist (miR‑146a‑A) and negative control (miR‑146a‑NC) were used to examine the effects of miR‑146a on OVX rats. The contents of osteocalcin and tartrate resistant phosphatase (TRAP) were detected via ELISA. Hematoxylin and eosin, and TRAP staining were used to observe the pathological changes and the number of osteoclasts in the jawbone, respectively. In addition, the expression levels of the nuclear factor of activated T cells c1 (NFATc1), c‑Fos and cathepsin K (CTK) in the jawbone were detected by immunohistochemistry, whereas the expression levels of osteoprotegerin, TRAP, dickkopf1, Wnt2 and β‑catenin in the same tissues were assessed by western blot analysis. The Wnt2 activator (DKK2‑C2) and inhibitor (endostatin) were used to examine the effects of miR‑146a on the Wnt/β‑catenin pathway. The results indicated that the BMD was increased, whereas the contents of osteocalcin and TRAP were decreased in the miR‑146a‑A group compared with those noted in the OP or negative control groups (P<0.05). Although the trabecular bone area of the OP group was decreased, the conditions were improved in the miR‑146a‑A group. The number of osteoclasts was decreased in the miR‑146a‑A group compared with that noted in the OP group (P<0.05). The expression levels of NFATc1, c‑Fos and CTK in the miR‑146a‑A group were decreased compared with those noted in the OP or negative control groups (P<0.05). Similar results were found following the comparison of the miR‑146a‑A group with the DKK2‑C2 group. Taken together, these data demonstrated that miR‑146a downregulation inhibited OP of the jawbone in OVX rats by activating the Wnt/β‑catenin signaling pathway.

View Figures

View References

1	Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ and Pelletier JP: Osteoarthritis. Nat Rev Dis Primers. 2:160722016. View Article : Google Scholar : PubMed/NCBI
2	Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet. 386:376–387. 2015. View Article : Google Scholar : PubMed/NCBI
3	Loeser RF, Goldring SR, Scanzello CR and Goldring MB: Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum. 64:1697–1707. 2012. View Article : Google Scholar : PubMed/NCBI
4	Van Spil WE, Kubassova O, Boesen M, Bay-Jensen AC and Mobasheri A: Osteoarthritis phenotype novel therapeutic targets. Biochem Pharmacol. 165:41–48. 2019. View Article : Google Scholar : PubMed/NCBI
5	O'Neill TW, McCabe PS and McBeth J: Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol. 32:312–326. 2018. View Article : Google Scholar : PubMed/NCBI
6	Kalaitzoglou E, Griffin TM and Humphrey MB: Innate immune responses and osteoarthritis. Curr Rheumatol Rep. 19:452017. View Article : Google Scholar : PubMed/NCBI
7	Kim JR, Jong Y and Hyun K: Therapeutics in osteoarthritis based on an Understanding of its molecular pathogenesis. Int J Mol Sci. 19:6742018. View Article : Google Scholar :
8	Herrero-Beaumont G, Pérez-Baos S, Sánchez-Pernaute O, Roman-Blas JA, Lamuedra A and Largo R: Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. Biochem Pharmacol. 165:24–32. 2019. View Article : Google Scholar : PubMed/NCBI
9	Gómez R, Villalvilla A, Largo R, Gualillo O and Herrero-Beaumont G: TLR4 signaling in osteoarthritis-finding targets for candidate DMOADs. Nat Rev Rheumatol. 11:159–170. 2014. View Article : Google Scholar
10	Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Nowand the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
11	Black DM and Rosen CJ: Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 374:254–262. 2016. View Article : Google Scholar : PubMed/NCBI
12	Manolagas SC and Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 332:305–311. 1995. View Article : Google Scholar : PubMed/NCBI
13	Sobacchi C, Schulz A, Coxon FP, Villa A and Helfrich MH: Osteopetrosis: Genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 9:522–536. 2013. View Article : Google Scholar : PubMed/NCBI
14	Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, Vanderschueren D and Manolagas SC: Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 97:135–187. 2017. View Article : Google Scholar :
15	Khosla S, Oursler MJ and Monroe DG: Estrogen and the skeleton. Trends Endocrinol Metab. 23:576–581. 2012. View Article : Google Scholar : PubMed/NCBI
16	Choi HK, Kim GJ, Yoo HS, Song DH, Chung KH, Lee KJ, Koo YT and An JH: Vitamin C activates osteoblastogenesis and inhibits osteoclastogenesis via Wnt/β-catenin/ATF4 signaling pathways. Nutrients. 11:5062019. View Article : Google Scholar
17	Lee KY, Kim JH, Kim EY, Yeom M, Jung HS and Sohn Y: Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat. BMC Complement Altern Med. 19:2072019. View Article : Google Scholar : PubMed/NCBI
18	Liu TJ and Guo JL: Overexpression of microRNA-141 inhibits osteoporosis in the jawbones of ovariectomized rats by regulating the Wnt/β-catenin pathway. Arch Oral Biol. 113:1047132020. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Ji X, Chen X and Yu X: MicroRNAs in osteoclastogenesis and function: Potential therapeutic targets for osteoporosis. Int J Mol Sci. 17:3492016. View Article : Google Scholar : PubMed/NCBI
21	Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46:D296–D302. 2018. View Article : Google Scholar :
22	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unifcation of biology. Te Gene Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
23	David C, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, Caudy M, Garapati P, Gillespie M, Kamdar MR, et al: The Reactome pathway knowledgebase. Nucleic Acids Res. 42(Database issue): D472–D477. 2014. View Article : Google Scholar
24	Zhao J, Huang M and Zhang X, Xu J, Hu G, Zhao X, Cui P and Zhang X: miR-146a deletion protects from bone loss in OVX mice by suppressing RANKL/OPG and M-CSF in bone microenvironment. J Bone Miner Res. 34:2149–2161. 2019. View Article : Google Scholar : PubMed/NCBI
25	Kim JH, Kim EY, Lee B, Min JH, Song DU, Lim JM, Eom JW, Yeom M, Jung HS and Sohn Y: The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells. Int J Mol Med. 37:649–658. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yao GQ, Troiano N, Simpson CA and Insogna KL: Selective deletion of the soluble colony-stimulating factor 1 isoform in vivo prevents estrogen-deficiency bone loss in mice. Bone Res. 5:170222017. View Article : Google Scholar :
27	Hu L, Su P, Yin C, Zhang Y, Li R, Yan K, Chen Z, Li D, Zhang G, Wang L, et al: Microtubule actin crosslinking factor 1 promotes osteoblast differentiation by promoting β-catenin/TCF1/Runx2 signaling axis. J Cell Physiol. 233:1574–1584. 2018. View Article : Google Scholar
28	Kahler RA and Westendorf JJ: Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem. 278:11937–11944. 2003. View Article : Google Scholar : PubMed/NCBI